3 completed, 1 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperammonemia: new trials by email Literature Review of Hyperammonemia trials Research Report on Hyperammonemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate Fezagepras, Sodium phenylbutyrate - Hyperammonemia | Phase 1 | Terminated | Liminal BioSciences Ltd. | 8 | 2022-05-13 | 2022-08-01 |
| PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia TNP-2092 capsules, Placebo - Hyperammonemia | Phase 1 / Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 36 | 2020-08-27 | 2025-04-25 |
| A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules TNP-2092 capsules, TNP-2092 placebo capsules - Hyperammonemia | Phase 1 | Completed | TenNor Therapeutics (Suzhou) Limited | 58 | 2016-06-06 | 2025-04-25 |
| Anaplerotic Therapy in Propionic Acidemia ornithine alpha ketoglutarate, glutamine, disodium citrate - Propionic Acidemia | Phase 1 | Completed | Nicola Longo | 3 | 2008-07-01 | 2015-01-21 |
Muscle Hypotonia (1) · Propionic Acidemia (1)
Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Amino Acid Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Nutritional and Metabolic Diseases (1) · Signs and Symptoms (1)
TNP-2092 (2) · 4-phenylbutyric acid (1) · Glutamic Acid (1) · Glutamine (1) · Sodium Citrate (1) · ornithine alpha-ketoglutarate (1) · setogepram (1)
TenNor Therapeutics (Suzhou) Limited (2) · Liminal BioSciences Ltd. (1) · Nicola Longo (1)
China (2) · United Kingdom (1) · United States (1)
Yanhua Ding, MD (2) · Nicola Longo, MD, PhD (1) · Sami Omar (1)
R21DK077415 (1)